Office of the Director

BmreauofCo~tition

. Fiona Schaeffer, Esq.

UNITED STATES OF AMERICA

FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

MAY 5 2010

Weil, Gotshal & Manges L.L.P.
767 Fifth Avenue
New York, New York 10153

Re: King-Arrow (AItace); FTC File No. 061-0192

Dear Ms. Schaeffer:

The Federal Trade Commission's Bureau of Competition has conducted a non-public investigation to determine whether, your client, Arrow International, Ltd. (which was recently acquired by Watson Pharmaceuticals, Inc.), and King Pharmaceuticals, Inc. engaged in, or are engaging in, unfair methods of competition in or affecting commerce in violation of Section 5 of the Federal Trade Commission Act, by agreeing

similar, the FDA may not consider the generic to be AB-rated to the new